• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用重组组织型纤溶酶原激活剂进行冠状动脉溶栓期间止血参数的监测。

Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.

作者信息

Stump D C, Topol E J, Chen A B, Hopkins A, Collen D

机构信息

Department of Medicine, University of Vermont College of Medicine, Burlington 05405.

出版信息

Thromb Haemost. 1988 Apr 8;59(2):133-7.

PMID:2455358
Abstract

The monitoring of changes in the blood coagulation and fibrinolytic systems during thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) may be complicated by artifacts due to in vitro activation after blood collection and to interference of other agents (e.g., heparin) in the assays. In 106 patients with early acute myocardial infarction, infused with 150 mg of rt-PA (G11044) intravenously over 5 to 8 hours, blood samples were collected into liquid citrate supplemented with the plasmin inhibitor aprotinin (200 KIU/ml plasma) or on a lyophilized mixture of acidified citrate and the synthetic t-PA inhibitor D-Phe-Pro-Arg-CH2Cl (PPACK). A good correlation between precipitable (sulphite) and functional (clotting rate) fibrinogen levels was observed in plasma collected on citrate before therapy (r = 0.76) and in samples collected after 3 hours on either aprotinin (r = 0.87) or PPACK (r = 0.82). Precipitable fibrinogen levels were approximately 10% higher than functional level, in baseline samples collected on citrate alone and approximately 20% higher in 3 hour samples collected on either PPACK or aprotinin. Fibrinogen levels measured with both assays correlated well, but were somewhat higher in samples collected on PPACK than on aprotinin. rt-PA antigen levels assayed in plasma collected in either inhibitor correlated well (r = 0.90) but were 10-20% higher in PPACK containing samples. Addition of heparin up to 9 units/ml to plasma had no effect on the functional fibrinogen assay.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在使用重组组织型纤溶酶原激活剂(rt-PA)进行溶栓治疗期间,监测血液凝固和纤维蛋白溶解系统的变化可能会因采血后体外激活以及检测中其他药物(如肝素)的干扰而出现假象。在106例早期急性心肌梗死患者中,静脉输注150mg rt-PA(G11044),持续5至8小时,将血样采集到添加纤溶酶抑制剂抑肽酶(200 KIU/ml血浆)的液体枸橼酸盐中,或采集到酸化枸橼酸盐与合成t-PA抑制剂D-苯丙氨酸-脯氨酸-精氨酸-氯甲基酮(PPACK)的冻干混合物上。在治疗前采集的枸橼酸盐血浆中以及在使用抑肽酶(r = 0.87)或PPACK(r = 0.82)采集3小时后的样本中,可沉淀(亚硫酸盐)纤维蛋白原水平与功能性(凝血速率)纤维蛋白原水平之间观察到良好的相关性。在仅采集于枸橼酸盐的基线样本中,可沉淀纤维蛋白原水平比功能性水平高约10%,在采集于PPACK或抑肽酶的3小时样本中高约20%。两种检测方法测得的纤维蛋白原水平相关性良好,但在采集于PPACK的样本中比在采集于抑肽酶的样本中略高。在采集于任何一种抑制剂中的血浆中检测的rt-PA抗原水平相关性良好(r = 0.90),但在含PPACK的样本中高10 - 20%。向血浆中添加高达9单位/ml的肝素对功能性纤维蛋白原检测无影响。(摘要截短于250字)

相似文献

1
Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.使用重组组织型纤溶酶原激活剂进行冠状动脉溶栓期间止血参数的监测。
Thromb Haemost. 1988 Apr 8;59(2):133-7.
2
D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy.D-苯丙氨酰-脯氨酰-精氨酰-氯甲基酮:其在抑制组织型纤溶酶原激活剂溶栓治疗期间采集的血液中体外假象形成方面的潜在用途。
Thromb Haemost. 1986 Oct 21;56(2):160-4.
3
Comparison of specific antibody, D-Phe-Pro-Arg-CH2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters.特异性抗体、D-苯丙氨酰-脯氨酰-精氨酸-氯甲基酮和抑肽酶对重组组织型纤溶酶原激活剂体外止血参数影响的预防作用比较
Thromb Haemost. 1987 Oct 28;58(3):921-6.
4
Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator.使用重组人组织型纤溶酶原激活剂进行溶栓治疗期间的止血实验室监测。
Thromb Res. 1988 Apr 1;50(1):121-33. doi: 10.1016/0049-3848(88)90180-6.
5
Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.心肌梗死溶栓治疗(TIMI)试验——I期:接受重组组织型纤溶酶原激活剂和链激酶治疗患者的出血表现以及血浆纤维蛋白原和纤溶系统的变化
J Am Coll Cardiol. 1988 Jan;11(1):1-11. doi: 10.1016/0735-1097(88)90158-1.
6
Markers of coagulation and fibrinolysis in blood drawn into citrate with and without D-Phe-Pro-Arg-Chloromethylketone (PPACK).在添加和不添加D-苯丙氨酸-脯氨酸-精氨酸-氯甲基酮(PPACK)的枸橼酸盐抗凝血液中凝血和纤溶标志物。
Thromb Res. 1994 Mar 1;73(5):279-84. doi: 10.1016/0049-3848(94)90024-8.
7
[Variations in hemostasis and fibrinolysis during the treatment of acute myocardial infarct (AMI) with tissue-type plasminogen activator (TTPA). A study of 17 cases].
Arch Inst Cardiol Mex. 1993 May-Jun;63(3):235-40.
8
Inhibition of desmoteplase-induced fibrinolytic activity in vitro.体外抑制去氨普酶诱导的纤溶活性。
J Thromb Thrombolysis. 2005 Aug;20(1):23-6. doi: 10.1007/s11239-005-2465-4.
9
[Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human].
Klin Wochenschr. 1988;66 Suppl 12:40-9.
10
[New thrombolytic agents in myocardial infarction].[心肌梗死中的新型溶栓药物]
Arch Mal Coeur Vaiss. 1987 Nov;80(12):1785-91.

引用本文的文献

1
Activated thrombin-activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation.活化的凝血酶激活的纤溶抑制物在体内生成的水平,可在黑猩猩体内因凝血酶生成而对纤维蛋白溶解产生显著影响。
J Thromb Haemost. 2008 Sep;6(9):1600-2. doi: 10.1111/j.1538-7836.2008.03067.x. Epub 2008 Jul 4.
2
Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.在大肠杆菌中产生的未糖基化重组组织型纤溶酶原激活剂(BM 06.021)的药代动力学和溶栓特性。
Naunyn Schmiedebergs Arch Pharmacol. 1992 Jul;346(1):108-13. doi: 10.1007/BF00167579.